Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation (HyTa Stent)

University of Kansas

Status and phase: Terminated; Phase 4

Conditions: Lower Urinary Tract Symptoms

Treatments: Drug: Tamsulosin; Drug: Hyoscyamine

Study type: Interventional

Funder types: Other

Identifiers

NCT03750656

HSC 142994

Details and patient eligibility

About

The objective of this project is to compare the efficacy of hyoscyamine to tamsulosin monotherapy in treating lower urinary tract symptoms in patients with indwelling double-J ureteral stents.

Full description

Ureteral stents are routinely used in a variety of urologic conditions. Unfortunately, indwelling ureteral stents commonly cause significant pain and discomfort due to irritation to the urinary system. Many studies have looked at methods to reduce these uncomfortable symptoms ranging from altering stent designs to pharmacologic therapies attempting to alleviate stent-discomfort. However, stent-related discomfort continues to be an issue and is often the cause of their removal earlier than planned. While the efficacy of certain alpha blockers and anticholinergics in treating stent-related symptoms have been studied, the data for the use of hyoscyamine in this setting is lacking. A literature search yielded no studies evaluating the use of hyoscyamine in this setting to date. The investigators hypothesize that hyoscyamine (brand name Levsin) is equivalent to tamsulosin in treating lower urinary tract symptoms in patients with indwelling double-J ureteral stents due to its anticholinergic properties. Furthermore, the investigators hypothesize that patients in the hyoscyamine arm will not require additional pain medications (e.g. Pyridium, narcotics) to help control stent-related discomfort compared to the tamsulosin arm.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must be 18 years of age or older
• Patient must require placement of a ureteral stent(s), per standard of care, following routine urological procedures including, but not limited to, ureteroscopy, stone extraction, or management of upper tract transitional cell carcinoma
• Patient must agree to abstain from other clinical studies during the study period

Exclusion criteria

• Patients younger than 18 years of age
• Patients with chronic or pre-existing indwelling stents
• Patients currently receiving anticholinergic or alpha blocker therapy
• Patients with chronic opioid or analgesic usage
• Patients with chronic pain syndrome or symptomatic benign prostatic hyperplasia
• Patients with an active untreated urinary tract infection
• Patients who are currently pregnant or nursing
• Patients with allergies or contraindication to either tamsulosin or hyoscyamine
• Patients on active chemotherapy
• Patients currently receiving other investigational therapy
• Patients who are unable to sign consent/answer questionnaire due to compromised mental capacity or language barrier (the questionnaire is not validated in other languages)
• Patients who have a stent placed emergently for an obstructing stone or septic stone without immediate stone removal,
• Any stents placed that will stay in for longer than 2 weeks

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

5 participants in 2 patient groups

Hyoscyamine

Active Comparator group

Description:

Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort

Treatment:

Drug: Hyoscyamine

Tamsulosin

Active Comparator group

Description:

0.4 mg tab orally daily

Treatment:

Drug: Tamsulosin